Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • CORRESPONDENCE

Equitable drug access: small-scale manufacturing units can help

  1. Rachel Chikwamba

    1. Council for Scientific and Industrial Research, Pretoria, South Africa.

    View author publications

    You can also search for this author in PubMed  Google Scholar

  2. Kerry R. Love

    1. Sunflower Therapeutics PBC, Hingham, Massachusetts, USA.

    View author publications

    You can also search for this author in PubMed  Google Scholar

  3. Anthony Bogachev

    1. Roivant Social Ventures, New York, New York, USA.

    View author publications

    You can also search for this author in PubMed  Google Scholar

  4. Ameer Basrai

    1. Roivant Social Ventures, New York, New York, USA.

    View author publications

    You can also search for this author in PubMed  Google Scholar

  5. Taylor Rose

    1. Roivant Social Ventures, New York, New York, USA.

    View author publications

    You can also search for this author in PubMed  Google Scholar

  6. Filippo Randazzo

    1. Leverage Science LLC, Berkeley, California, USA.

    View author publications

    You can also search for this author in PubMed  Google Scholar

Low- and middle-income countries (LMICs) need to build their domestic drug-manufacturing capabilities beyond just vaccine production (see Nature 602, 184; 2022). Innovative production systems are emerging that could markedly increase their access to vaccines and therapeutics (see go.nature.com/3wjijgb).

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Learn more

Prices may be subject to local taxes which are calculated during checkout

Nature 609, 245 (2022)

doi: https://doi.org/10.1038/d41586-022-02803-8

Competing Interests

K.R.L. is an owner, shareholder and employee of Sunflower Therapeutics PBC. Ameer Basrai is an employee and shareholder of Roivant Sciences. Anthony Bogachev is an employee of Roivant Social Ventures and a shareholder of Rovant Sciences. F.R. is a consultant for the Bill & Melinda Gates Foundation and a member of the board of directors of VaxThera, a Sura Company.

Subjects

Latest on:

Nature Careers

Jobs

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing

Search

Advanced search

Quick links